Type 2 Diabetes Mellitus Therapeutic Market Report 2025 (Global Edition)

Global Type 2 Diabetes Mellitus Therapeutic Market Report 2024 Market Size Split by Drug Class Outlook: (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Others), by Route of Admi...

Type 2 Diabetes Mellitus Therapeutic Market Report Description

We have various report editions of Type 2 Diabetes Mellitus Therapeutic Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Type 2 Diabetes Mellitus Therapeutic Market Insights Video

Competitive Landscape of the Type 2 Diabetes Mellitus Therapeutic Market

The Type 2 diabetes mellitus therapeutic market is highly competitive, with key players dominating a diverse portfolio of medications such as GLP-1 receptor agonists, SGLT2 inhibitors, and insulin therapies. Innovation and partnerships drive competition, with firms focusing on developing next-generation drugs, improving patient outcomes, and expanding market reach. Additionally, market players are investing in digital health solutions and personalized medicine to enhance diabetes management.

In April 2024, Sanofi launched its diabetes medication Soliqua in India following the receipt of marketing authorization from the Central Drugs Standard Control Organization (CDSCO). This introduction marks a significant expansion of Sanofi's diabetes care offerings in the Indian market. (Source: https://www.sanofi.in/dam/jcr:00aa3c72-86bf-4973-81f6-862238b832d4/Sanofi-India-receives-marketing-approval-for-its-diabetes-drug-Soliqua-in-India.pdf) In May 2022, the US Food and Drug Administration (FDA) granted approval for Mounjaro (tirzepatide), an injection developed by Eli Lilly to enhance blood sugar control in adults with Type 2 diabetes (T2D). (Source: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-mounjarotm-tirzepatide-injection-first-and#:~:text=INDIANAPOLIS%20%2C%20May%2013%2C%202022%20%2F,as%20an%20adjunct%20to%20diet)

Top Companies Market Share in Type 2 Diabetes Mellitus Therapeutic Industry: (In no particular order of Rank)

• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Co. Ltd
• Eli Lilly and Co.
• Merck & Co. Inc
• Novartis AG
• Novo Nordisk AS
• Sanofi SA
• Takeda Pharmaceutical Co. Ltd
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Type 2 Diabetes Mellitus Therapeutic Market

Which Region Dominates the Type 2 Diabetes Mellitus Therapeutic Market in 2024?

According to Cognitive Market Research, North America currently dominates the Type 2 Diabetes Mellitus Therapeutics market, and the region is expected to have significant growth during the projected period. This is due to the high prevalence rates of diabetes, advanced healthcare infrastructure, and strong adoption of innovative treatments.

Which Region is Expanding at the Fastest CAGR?

Asia-Pacific is expected to make significant gains during the projected period, with the greatest compound annual growth rate (CAGR). The rising prevalence of Type 2 diabetes, coupled with improved healthcare access and government initiatives, is driving demand for advanced treatments across the region.

The current report Scope analyzes Type 2 Diabetes Mellitus Therapeutic Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Type 2 Diabetes Mellitus Therapeutic

According to Cognitive Market Research, the global Type 2 Diabetes Mellitus Therapeutic market size was estimated at USD 19514.5 Million, out of which North America held the major market share of more than 40% of the global revenue with a market size of USD 7805.80 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Type 2 Diabetes Mellitus Therapeutic market with a market size of USD 6158.78 million in 2024 and is projected to grow at a CAGR of 6.8% during the forecast period due to the advancements in diabetes management technologies.
• The Canada Type 2 Diabetes Mellitus Therapeutic market had a market share of USD 936.70 million in 2024 and is projected to grow at a CAGR of 7.8% during the forecast period due to increased awareness and early diagnosis.
• The Mexico Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 710.33 million in 2024.

Europe Type 2 Diabetes Mellitus Therapeutic

According to Cognitive Market Research, the global Type 2 Diabetes Mellitus Therapeutic market size was estimated at USD 19514.5 Million, out of which Europe held the market share of more than 30% of the global revenue with a market size of USD 5854.35 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.3% from 2024 to 2031.

• The United Kingdom Type 2 Diabetes Mellitus Therapeutic market had a market share of USD 983.53 million in 2024 and is projected to grow at a CAGR of 8.1% during the forecast period. In the UK, Type 2 Diabetes Mellitus Therapeutic sales witness an upswing due to the advancements in diabetes management and drug development.
• The France Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 538.60 million in 2024.
• According to Cognitive Market Research, the German Type 2 Diabetes Mellitus Therapeutic market size was valued at USD 1159.16 million in 2024 and is projected to grow at a CAGR of 7.5% during the forecast period. In Germany, Type 2 Diabetes Mellitus Therapeutic surged due to the growing government initiatives and healthcare investments.
• The Italy Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 503.47 million in 2024.
• The Russia Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 6.3% during the forecast period, with a market size of USD 907.42 million in 2024.
• The Spain Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 6.4% during the forecast period with a market size of USD 480.06 million in 2024
• The Luxembourg Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 7.4% during the forecast period, with a market size of USD 181.48 million in 2024.
• The Portugal Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 7.1% during the forecast period, with a market size of USD 122.94 million in 2024.
• The Greece Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD 70.25 million in 2024.
• The Rest of Europe's Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 6.0% during the forecast period, with a market size of USD 907.42 million in 2024.

Asia Pacific Type 2 Diabetes Mellitus Therapeutic

According to Cognitive Market Research, the global Type 2 Diabetes Mellitus Therapeutic market size was estimated at USD 19514.5 Million, out of which Asia Pacific held the market share of around 23% of the global revenue with a market size of USD 4488.34 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.8% from 2024 to 2031.

• According to Cognitive Market Research, the China Type 2 Diabetes Mellitus Therapeutic market size was valued at USD 2019.75 million in 2024 and is projected to grow at a CAGR of 10.3% during the forecast period. Type 2 Diabetes Mellitus Therapeutic surged in China due to the increasing healthcare investments and access to treatment.
• The Japan Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 619.39 million in 2024.
• The India Type 2 Diabetes Mellitus Therapeutic market had a market share of USD 538.60 million in 2024 and is projected to grow at a CAGR of 12.6% during the forecast period due to the growing awareness and adoption of diabetes management solutions.
• The South Korean Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 9.9% during the forecast period, with a market size of USD 448.83 million in 2024.
• The Australian Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 10.5% during the forecast period, with a market size of USD 233.39 million in 2024.
• The South East Asia Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 11.8% during the forecast period, with a market size of USD 309.70 million in 2024.
• The Rest of Asia Pacific Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 10.6% during the forecast period, with a market size of USD 318.67 million in 2024.

South America Type 2 Diabetes Mellitus Therapeutic

According to Cognitive Market Research, the global Type 2 Diabetes Mellitus Therapeutic market size was estimated at USD 19514.5 Million, out of which Latin America held the market share of around 5% of the global revenue with a market size of USD 975.73 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Type 2 Diabetes Mellitus Therapeutic market size was valued at USD 417.61 million in 2024 and is projected to grow at a CAGR of 8.8% during the forecast period. Type 2 Diabetes Mellitus Therapeutics flourished in Brazil due to the increasing prevalence of type 2 diabetes.
• Argentina's Type 2 Diabetes Mellitus Therapeutic market had a market share of USD 163.92 million in 2024 and is projected to grow at a CAGR of 9.1% during the forecast period due to the rising healthcare investments and access.
• Colombia's Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 86.84 million in 2024.
• Peru's Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 8.4% during the forecast period, with a market size of USD 80.01 million in 2024.
• Chile's Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 70.25 million in 2024.
• The Rest of Latin America's Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 7.3% during the forecast period, with a market size of USD 157.09 million in 2024.

Middle East and Africa Type 2 Diabetes Mellitus Therapeutic

According to Cognitive Market Research, the global Type 2 Diabetes Mellitus Therapeutic market size was estimated at USD 19514.5 Million, out of which the Middle East and Africa held the major market share of around 2% of the global revenue with a market size of USD 390.29 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2031..

• The GCC Countries Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 167.04 million in 2024. Type 2 Diabetes Mellitus Therapeutic sales flourish due to the increasing healthcare infrastructure and access.
• The Egypt Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 8.8% during the forecast period, with a market size of USD 40.68 million in 2024.
• The South Africa Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 9.5% during the forecast period, with a market size of USD 61.67 million in 2024. Type 2 Diabetes Mellitus Therapeutic sales flourished in South Africa due to the growing awareness and adoption of diabetes management programs.
• The Turkey Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 8.0% during the forecast period, with a market size of USD 33.56 million in 2024.
• The Nigeria Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD 40.98 million in 2024.
• The Rest of the MEA Type 2 Diabetes Mellitus Therapeutic market is projected to witness growth at a CAGR of 7.5% during the forecast period, with a market size of USD 46.05 million in 2024.

Type 2 Diabetes Mellitus Therapeutic Market Analysis

How are Segments Performing in the Global Type 2 Diabetes Mellitus Therapeutic Market?

Type 2 Diabetes Mellitus Therapeutic Market Drug Class Segment Analysis

According to Cognitive Market Research, insulin is likely to dominate the Type 2 Diabetes Mellitus Therapeutic Market over the forecast period due to its long-established efficacy in controlling blood sugar levels, particularly in advanced stages of the disease. As a cornerstone of diabetes management, insulin therapy is widely prescribed, making it a crucial component in the treatment of Type 2 diabetes.

The SGLT2 inhibitors are the fastest-growing segment in the Type 2 Diabetes Mellitus Therapeutic Market due to their dual benefits of lowering blood sugar and reducing cardiovascular and renal risks. Their effectiveness in managing diabetes complications, combined with growing clinical evidence and approval for broader indications, drives rapid adoption.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Type 2 Diabetes Mellitus Therapeutic Industry. Request a Free Sample PDF!

Type 2 Diabetes Mellitus Therapeutic Market Route of Administration Segment Analysis

According to Cognitive Market Research, the oral segment holds the largest share of the market due to its convenience, ease of administration, and cost-effectiveness compared to injectable therapies. Drugs like metformin, sulfonylureas, and newer oral agents such as SGLT2 inhibitors and DPP-4 inhibitors are preferred by patients, driving widespread adoption and market growth.

In the Type 2 Diabetes Mellitus Therapeutic Market, subcutaneous therapies, particularly GLP-1 receptor agonists and insulin injections, are the fastest-growing segment. Their increasing adoption is driven by their effectiveness in controlling blood sugar, ease of self-administration, and the convenience of at-home use, offering significant benefits over oral treatments.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Type 2 Diabetes Mellitus Therapeutic Distribution Channel Outlook: Segment Analysis

Type 2 Diabetes Mellitus Therapeutic Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the retail pharmacies segment holds the largest market share by providing convenient access to a wide range of medications, including insulin and oral drugs. Their widespread availability, competitive pricing, and personalized services, such as diabetes management counselling, make them a preferred choice for patients seeking continuous treatment.

In the Type 2 Diabetes Mellitus Therapeutic market, the rapidly growing sector is the hospital pharmacies category due to the increasing hospitalization rates of diabetic patients. Hospitals provide comprehensive diabetes management, offering a wide range of treatments, including advanced therapies, insulin regimens, and monitoring systems, driving the demand for therapeutic solutions in clinical settings.

• Retail Pharmacies
• Hospital Pharmacies
• Other

Author's Detail

Manjiri Kanhere

Senior Research Associate at Cognitive Market Research

LinkedIn

Profile

Manjiri Kanhere is an experienced market researcher focused on the Pharma & Healthcare industry. With over 3+ years of experience, She has worked with major pharmaceutical companies and healthcare providers, helping them to understand market trends, identify new business opportunities, and develop effective sales & marketing strategies. Her expertise lies in the ability to analyze complex data sets and deliver insights that drive business decisions. At Cognitive Market Research, she handles the market research related to Pharma and healthcare industry.

Author's Conclusion